NVP-QBE170

• Description:

  NVP-QBE170 is a selective Epithelial sodium channel (ENaC) inhibitor with an IC50 of 57.5 nM. NVP-QBE170 potently inhibits ENaC function in HBECs and shows a longer duration of action. NVP-QBE170 significantly attenuates ENaC activity in the airways of guinea pig models. NVP-QBE170 can be used for hyperkalaemia research[1].

• UNSPSC:

  12352100

• Target:

  Sodium Channel

• Related Pathways:

  Membrane Transporter/Ion Channel

• Field of Research:

  Metabolic Disease

• Smiles:

  O=C (C1=NC (Cl) =C (N) N=C1N) NC (NC2CCN (CC2) C (C3=CC=C (C (N4CCC (CC4) NC (NC (C5=NC (Cl) =C (N) N=C5N) =O) =N) =O) C=C3) =O) =N

• Molecular Formula:

  C30H36Cl2N16O4

• Molecular Weight:

  755.62

• References & Citations:

  [1]Coote KJ, et al. NVP-QBE170: an inhaled blocker of the epithelial sodium channel with a reduced potential to induce hyperkalaemia. Br J Pharmacol. 2015 Jun;172 (11) :2814-26.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  1080018-61-6